Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease
Neurol Ther
.
2024 Sep 12.
doi: 10.1007/s40120-024-00660-3.
Online ahead of print.
Authors
Samuel Frank
1
,
Karen E Anderson
2
,
Hubert H Fernandez
3
,
Robert A Hauser
4
,
Daniel O Claassen
5
,
David Stamler
6
,
Stewart A Factor
7
,
Joohi Jimenez-Shahed
8
,
Hadas Barkay
9
,
Amanda Wilhelm
10
,
Jessica K Alexander
10
,
Nayla Chaijale
10
,
Steve Barash
10
,
Juha-Matti Savola
11
,
Mark Forrest Gordon
10
,
Maria Chen
10
Affiliations
1
Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Ave., Kirstein 228, Boston, MA, 02215, USA.
[email protected]
.
2
Georgetown University, Washington, DC, USA.
3
Cleveland Clinic, Cleveland, OH, USA.
4
University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL, USA.
5
Vanderbilt University Medical Center, Nashville, TN, USA.
6
Teva Branded Pharmaceutical Products R&D, Inc., La Jolla, CA, USA.
7
Emory University, Atlanta, GA, USA.
8
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
9
Teva Pharmaceutical Industries Ltd., Netanya, Israel.
10
Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
11
Teva Pharmaceuticals International GmbH, Basel, Switzerland.
PMID:
39266813
DOI:
10.1007/s40120-024-00660-3
No abstract available
Publication types
Published Erratum